Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 26, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares, authorized by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,900,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,226.53 pence per share.
- Treasury Holdings: 467,014,158 shares (representing 8.40% of total voting rights).
- Shares in Issue: 5,557,966,834 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the purchase of 1,900,000 shares on October 26, 2007. These shares are intended to be held in Treasury. Consequently, the total number of shares in issue (excluding Treasury) remains 5,557,966,834, which serves as the denominator for shareholder notification calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,557,966,834) for accurate calculation of ownership percentages under Disclosure and Transparency Rules.
- Confirm the current Treasury share count (467,014,158) and its impact on total voting rights (8.40%).
- Note that this filing is a transactional report and does not include operational or financial performance data for the period.